Differences In Selection Criteria Among Traditional Students, Adult Continuing Education Students And Graduate Students

This paper examines college selection cues and criteria differences among three important segments of students. These segments were traditional undergraduate students, adult continuing education students and graduate students. There were significant differences among the a-priori defined segments

Biophysical Methods for Attomolar Detection of Compounds Acting on Protein Oligomer States

Few protocols exist today that demonstrate repeatable resolution of small molecule interactions with target proteins at extremely low analyte levels, particularly at sub-femtomolar levels. We have developed two approaches for rapid screening and biophysical analysis which leverage changes in protein oligomer states to study highly potent drug candidates. The first protocol employs microscale thermophoresis (MST) to measure competitive disruption of oligomerization following exposure of the target protein to its endogenous ligand. The second protocol engages dynamic light scattering (DLS) to measure the changes in physical size of oligomers after exposure endogenous ligand and/or analyte. We demonstrate the utilization of these methods through measurements of stimulator of interferon genes (STING) exposure to 2’,3’-cGAMP and the drug candidate clonixeril along with several analog compounds that were created for lead optimization

License Analysis of e-Journal Perpetual Access

In this paper we investigate the definitions of perpetual access and examine current studies on the attitudes and concerns towards perpetual access from both libraries and publishers separately. We then conduct a content analysis of 72 e-journal licenses to explore whether perpetual access clauses vary among commercial publishers and non-commercial publishers, whether clauses change over time, and whether differences exist between consortium and site licenses. Results suggest that different perpetual access clauses may be at different stages of institutionalization. Perpetual access clauses that are more institutionalized include: addressing perpetual access in license, providing perpetual access upon expiry of subscription, and specifying a location for perpetual access

Extending thrombolysis to 4·5–9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data

Background: Stroke thrombolysis with alteplase is currently recommended 0–4·5 h after stroke onset. We aimed to determine whether perfusion imaging can identify patients with salvageable brain tissue with symptoms 4·5 h or more from stroke onset or with symptoms on waking who might benefit from thrombolysis. Methods: In this systematic review and meta-analysis of individual patient data, we searched PubMed for randomised trials published in English between Jan 1, 2006, and March 1, 2019. We also reviewed the reference list of a previous systematic review of thrombolysis and searched ClinicalTrials.gov for interventional studies of ischaemic stroke. Studies of alteplase versus placebo in patients (aged ≥18 years) with ischaemic stroke treated more than 4·5 h after onset, or with wake-up stroke, who were imaged with perfusion-diffusion MRI or CT perfusion were eligible for inclusion. The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score 0–1) at 3 months, adjusted for baseline age and clinical severity. Safety outcomes were death and symptomatic intracerebral haemorrhage. We calculated odds ratios, adjusted for baseline age and National Institutes of Health Stroke Scale score, using mixed-effects logistic regression models. This study is registered with PROSPERO, number CRD42019128036. Findings: We identified three trials that met eligibility criteria: EXTEND, ECASS4-EXTEND, and EPITHET. Of the 414 patients included in the three trials, 213 (51%) were assigned to receive alteplase and 201 (49%) were assigned to receive placebo. Overall, 211 patients in the alteplase group and 199 patients in the placebo group had mRS assessment data at 3 months and thus were included in the analysis of the primary outcome. 76 (36%) of 211 patients in the alteplase group and 58 (29%) of 199 patients in the placebo group had achieved excellent functional outcome at 3 months (adjusted odds ratio [OR] 1·86, 95% CI 1·15–2·99, p=0·011). Symptomatic intracerebral haemorrhage was more common in the alteplase group than the placebo group (ten [5%] of 213 patients vs one [<1%] of 201 patients in the placebo group; adjusted OR 9·7, 95% CI 1·23–76·55, p=0·031). 29 (14%) of 213 patients in the alteplase group and 18 (9%) of 201 patients in the placebo group died (adjusted OR 1·55, 0·81–2·96, p=0·66). Interpretation: Patients with ischaemic stroke 4·5–9 h from stroke onset or wake-up stroke with salvageable brain tissue who were treated with alteplase achieved better functional outcomes than did patients given placebo. The rate of symptomatic intracerebral haemorrhage was higher with alteplase, but this increase did not negate the overall net benefit of thrombolysis